Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib

• Main Authors: Chiara Dalle Fratte (Author), Michela Guardascione (Author), Elena De Mattia (Author), Eugenio Borsatti (Author), Roberta Boschetto (Author), Angelo Farruggio (Author), Vincenzo Canzonieri (Author), Loredana Romanato (Author), Rachele Borsatti (Author), Sara Gagno (Author), Elena Marangon (Author), Maurizio Polano (Author), Angela Buonadonna (Author), Giuseppe Toffoli (Author), Erika Cecchin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The standard of care for the first-line treatment of advanced gastrointestinal stromal tumor (GIST) is represented by imatinib, which is given daily at a standard dosage until tumor progression. Resistance to imatinib commonly occurs through the clonal selection of genetic mutations in the tumor DNA...